Author

M. Pollak

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Organism:mouse· 3 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

J. Zeng· 2 shared Y. Wang· 2 shared A. L. Kucinskas· 1 shared A. M. Laughney· 1 shared A. N. Ho· 1 shared B. D. Hopkins· 1 shared B. K. Subramanian· 1 shared B. P. Riesenberg· 1 shared

Activity by Year

2017-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Zeng

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Tirzepatide restricts obesity-related tumor growth by reversing metabolic dysregulation and rescuing CD8+ T cell function

E. M. Glenny, M. F. Coleman, G. T. Clutton, B. P. Riesenberg, A. N. Ho, T. L. McFarlane, V. A. Kiesel, A. L. Kucinskas, E. G. Bailey, K. E. Sanchez, J. Zeng, Y. Wang, H. M. Malian, C. E. Gates, F. Chen, , S. D. Hursting

This study shows tirzepatide reduces obesity-related tumor growth by improving metabolism and restoring CD8+ T cell function without directly targeting cancer cells.

bioRxiv · Jan 20, 2024 · PreprintCancer Biology

Tirzepatide inhibits tumor growth in mice with diet-induced obesity

L. Huang, J. Zeng, Y. Wang, M. Pollak

Tirzepatide reduces tumor growth in obese mice by decreasing food intake and metabolic hormones, but not by directly inhibiting cancer cell proliferation.

bioRxiv · Jun 22, 2023 · PreprintCancer Biology

Obesity promotes breast epithelium DNA damage in BRCA mutation carriers

P. Bhardwaj, N. M. Iyengar, H. Zahid, K. M. Carter, D. J. Byun, M.-H. Choi, Q. Sun, O. Savenkov, C. Louka, C. Liu, P. Piloco, M. Acosta, R. Bareja, O. Elemento, M. Foronda, , K. A. Brown

The paper shows that obesity increases DNA damage in breast epithelium of BRCA mutation carriers and suggests targeting estrogen or metabolic dysfunction may reduce breast cancer risk.

bioRxiv · Jul 29, 2022 · PreprintCancer Biology

Proteolytic program-dependent functions are impaired in INF2-mediated focal segmental glomerulosclerosis.

B. K. Subramanian, J. Chun, C. Perez, P. Yan, I. Stillman, H. Higgs, S. Alper, J. Schlondorff, M. Pollak

This study identifies a proteolytic cleavage mechanism in INF2 that affects its function in podocytes, leading to impaired localization and contributing to FSGS.

bioRxiv · Jan 26, 2019 · PreprintPathology

Translational and HIF1α-dependent metabolic reprograming underpin oncometabolomeplasticity and synergy between oncogenic kinase inhibitors and biguanides.

L. Hulea, S.-P. Gravel, M. Morita, M. Cargnello, O. Uchenunu, Y. K. Im, S. McLaughlan, O. Larsson, M. Ohh, T. Ferreira, C. Greenwood, G. Bridon, D. Avizonis, J. Ursini-Siegel, J. St-Pierre, , I. Topisirovic

This study identifies translational reprogramming of non-essential amino acid synthesis and HIF1-dependent reductive glutamine metabolism as key factors enabling synergy between kinase inhibitors and biguanides in cancer cells.

bioRxiv · Jul 8, 2017Cancer Biology